Efficient-secretion canine parvovirus resistant monoclonal antibody hybridoma cell A135 strain

Abstract

The invention relates to an efficient-secretion canine parvovirus (CPV) resistant monoclonal antibody hybridoma cell A135 strain and belongs to the technical field of biology. The hybridoma cell A135 strain selected from the secretion CPV resistant monoclonal antibody hybridoma cell bank is excellent in biological performance and is injected with ascetic fluid generated in a BALB / C mouse peritoneal, so that neutralizing titer is up to 1010. In addition, the hybridoma cell A135 strain has moderate neutralizing capacity for various CPV subtype virus strain such as CPV-2a, CPV-2b, CPV-2c (a) and CPV-2c (b) and CPV strains from foxes and raccoon dogs, is wide in anti-CPV strain range and is used for clinical treatment of attacked dogs with CPV diseases, and effective rate is up to 100%.

Description

technical field

[0001] The invention relates to a hybridoma cell highly secreting anti-canine parvovirus (CPV) monoclonal antibody, belonging to the field of biotechnology. Background technique

[0002] Canine parvovirus disease (CPVD) is a canine viral infectious disease caused by canine parvovirus (CPV), characterized by hemorrhagic enteritis or non-suppurative myocarditis. The disease is highly contagious , The mortality rate is high, dogs of all ages can be infected, the mortality rate of puppies is as high as 70%, and the economic loss caused by the disease is huge. Although CPVD vaccination has been widely adopted for susceptible dogs, CPV is still one of the most serious infectious diseases that endanger the dog industry in my country because of its strong resistance to the outside world and easy mutation.

[0003] CPV (also known as CPV-2) is a new type of parvovirus isolated from the stool of dogs with hemorrhagic enteritis by American scholars in 1977. Virus (min...